HRT Prioritizes Access To Affordable Naloxone As US FDA Approves Second OTC Formulation

 
• By Malcolm Spicer

Co-founder and CEO Michael Hufford says HRT hopes to distribute first commercial supply in early 2024. Firm is engaging additional funding partners to help make its affordable opioid overdose treatment more accessible.

RiVive nasal spray is second OTC naloxone formulation approved in US. • Source: Harm Reduction Therapeutics

More from Rx-to-OTC Switch

More from Health